The muscle-sparing profile in combination with GLP-1 therapy is a differentiated value proposition in the obesity space. Watch for IND filing and Phase 1 initiation in H1 2027 as the next catalyst; any partnership interest from large pharma would be a significant validation event.
Price Chart
Executive Summary
iBio released preclinical body-composition data from an obese NHP study of IBIO-610, a first-in-class Activin E antibody, showing that when combined with semaglutide, 93% of weight lost came from fat vs 77% with semaglutide alone, and lean mass comprised only 6% of weight loss vs 22%. The company plans to begin first-in-human studies in the first half of 2027. This is an early-stage preclinical data readout with no financial figures or regulatory milestones.
Key Facts
- IBIO-610 plus semaglutide: 93% of weight lost from fat vs 77% with semaglutide alone
- Lean mass made up 6% of weight loss with IBIO-610 plus semaglutide vs 22% with semaglutide alone
- IBIO-610 demonstrated 97% reduction in serum active Activin E at week 8 after a single IV dose
- IBIO-610 had a 33.2-day half-life in NHPs, with projected human half-life potentially supporting twice-yearly dosing
- First-in-human studies planned for first half of 2027
Financial Impact
No financial figures disclosed; preclinical data only
Risk Factors
- Preclinical NHP results may not replicate in human trials
- Company is pre-revenue clinical-stage with no approved products; capital needs for Phase 1 are unstated
- Competitive obesity landscape includes many well-funded GLP-1 and muscle-preservation candidates
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001420720-26-000030 |
| Document: ibio-ex99d1.htm | 0001420720-26-000030 |
| Document: 0001420720-26-000030-index-headers.html | 0001420720-26-000030 |
| Document: 0001420720-26-000030-index.html | 0001420720-26-000030 |
| Document: 0001420720-26-000030.txt | 0001420720-26-000030 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | 8-K | $0.8210 $0.7669 | ▼ −6.59% | ▼ −6.67% | $0.7700 (−6.21%) |
Oct 14, 2026 13d ago | SC 13G | $0.7808 $0.8400 | ▲ +7.58% | ▲ +7.13% | $0.7700 (−1.38%) |
Oct 13, 2026 14d ago | 8-K | $0.7818 $0.8210 | ▲ +5.01% | ▲ +6.17% | $0.7700 (−1.51%) |
Sep 14, 2026 6w ago | 8-K | $1.19 $1.33 | ▲ +11.76% | ▲ +9.64% | $0.7700 (−35.29%) |
Aug 28, 2026 8w ago | 8-K | $1.36 $1.31 | ▼ −3.68% | ▼ −3.79% | $0.7700 (−43.38%) |
Aug 28, 2026 8w ago | Press Release | $1.36 $1.31 | ▼ −3.68% | ▼ −3.79% | $0.7700 (−43.38%) |
Jul 1, 2026 16w ago | 8-K | $1.75 $1.59 | ▼ −9.14% | ▼ −9.40% | $0.7700 (−56.00%) |
May 15, 2026 23w ago | 3 | $1.47 $1.84 | ▲ +25.17% | ▲ +24.21% | $0.7700 (−47.62%) |
May 12, 2026 24w ago | Press Release | $1.55 $1.50 | ▲ +3.23% | ▲ +2.07% | $0.7700 (+50.32%) |
May 8, 2026 24w ago | 8-K | $1.66 $1.42 | ▼ −14.46% | ▼ −14.37% | $0.7700 (−53.61%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers